Science 37 Holdings, Inc. Common Stock

SNCE

Market cap $34.7M

MORRISVILLE, N.C., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Science 37 , a leader in enhancing patient access to clinical trials, today announced the successful completion of its third FDA inspection, further affirming the quality and compliance of its Direct-to-Patient Site for clinical research.

Science 37 and Catalent announce a strategic partnership enabling direct-to-patient investigational medicinal product (IMP) delivery for clinical research.

MORRISVILLE, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Science 37 , a leader in enhancing patient access to clinical trials, today announced the grand opening of its new, 19,000-square-foot corporate headquarters in Morrisville, North Carolina, in the heart of Research Triangle Park.

RESEARCH TRIANGLE PARK, N.C., June 27, 2024 (GLOBE NEWSWIRE) -- Science 37 , a leader in enhancing patient access to clinical trials, has been added to over 20 studies that were lagging in recruitment, helping them to trend back towards their projected targets.

RESEARCH TRIANGLE PARK, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Science 37, Inc., please note that the first sentence of the second paragraph has been revised.

RESEARCH TRIANGLE PARK, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. today announced the preliminary outcome of its recent FDA Inspection focusing on critical areas and documentation.

Science 37 announces its selection as the winner of the “Clinical Efficiency Innovation Award” in the 8th annual MedTech Breakthrough Awards program.

RESEARCH TRIANGLE PARK, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. today disclosed the latest enrollment figures resulting from its Metasite™ and Patient Recruitment partnership with a leading biotech company whose asthma drug is currently undergoing a Phase 3 clinical trial.

RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc., the clinical research industry's leading MetasiteTM, today announced the launch of a stand-alone Patient Recruitment Solution to deliver patients to sites that are eligible, medically reviewed, and fully consented.

MIAMI , March 12, 2024 /PRNewswire/ -- eMed, LLC ("eMed") today announced the successful completion of the previously announced tender offer by its wholly-owned subsidiary, Marlin Merger Sub Corporation ("Purchaser"), for all the outstanding shares of common stock, par value $0.0001 per share, of Science 37 Holdings, Inc. (NASDAQ: SNCE) ("Science 37") at a price of USD 5.75 per share. Continental Stock Transfer & Trust Company, the depositary for the tender offer, has advised Purchaser that, as of 12:00 Midnight, New York City time, at the end of the day of Monday, March 11, 2024 (the "Expiration Time"), the expiration of the tender offer, (i) 4,715,950 shares were validly tendered and not withdrawn in the tender offer, representing approximately 77.8% of Science 37's outstanding shares of common stock, and (ii) notices of guaranteed delivery had been delivered with respect to 76,755 additional shares, representing approximately 1.3% of the outstanding shares.